Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
Clinical trial NCT05445934 · UNKNOWN
Trial details
- NCT number
- NCT05445934
- Sponsor
- Frontier Biotechnologies Inc.
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-14
- Primary completion
- 2023-11-01
- Enrollment
- 1188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.